FDA partially lifts hold on development of novel kinase inhibitor

19 August 2022
curis_large

Shares in oncology company Curis (Nasdaq: CRIS) rose by around 15% on Thursday, after the US Food and Drug Administration lifted a partial clinical hold on the Phase I/II TakeAim Lymphoma trial.

The program is investigating emavusertib, a novel blocker of the IRAK4 kinase, which plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways.

Curis - which has retained its confidence in the program throughout - said the US regulator made the decision after reviewing the "comprehensive data package" submitted by the firm.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology